CompletedNCT05545111
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia
This study evaluated the safety and effectiveness of NBI-1117568 for people with schizophrenia.
Medication studyAges 18–55United States
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of NBI-1117568 for people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
- Listed locations
- Little Rock, United States · Rogers, United States and 13 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateStarted: October 4, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 210
- Sponsor
- Neurocrine Biosciences
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT05545111
- Official title
Show the full official title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization
Recruitment & locations
CompletedLittle Rock · Rogers · Lemon Grove
12 more locations
- Pico Rivera
- San Diego
- Torrance
- Miami Lakes
- Oakland Park
- Gaithersburg
- St Louis
- Berlin
- North Canton
- Austin
- DeSoto
- Richardson
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of NBI-1117568 for people with schizophrenia.
Who is behind this study?
The study sponsor is Neurocrine Biosciences, a biotech company.
Did this study involve medication?
Yes. The study involved medication, including NBI-1117568 and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT01157351
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
United States
CompletedNCT06880328
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in people with Schizophrenia
United States
CompletedNCT01714713
EVP-6124 (Alpha-7 nAChR) for schizophrenia
This study evaluated the safety of EVP-6124 for people with schizophrenia.